Does impaired HDL anti-inflammatory capacity reflect residual atherosclerotic risk or cardiorenal vulnerability?

Scritto il 30/07/2026
da Zhaonan Li

No abstract

J Clin Lipidol. 2026 Jul 3:S1933-2874(26)00402-2. doi: 10.1016/j.jacl.2026.06.010. Online ahead of print.

NO ABSTRACT

PMID:42532707 | DOI:10.1016/j.jacl.2026.06.010